CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1



Status:Recruiting
Conditions:Endocrine, Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:6 - 45
Updated:1/28/2018
Start Date:March 2013
End Date:November 2020
Contact:Lisa E Rafkin, MS
Email:lrafkin@miami.edu
Phone:305-243-6146

Use our guide to learn which trials are right for you!

CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Diabetes

The study is a 2-arm, multicenter, 1:1 randomized, placebo controlled clinical trial.

All subjects will receive close monitoring for development of AGT or T1DM. Subjects will
receive Abatacept or placebo and close monitoring for development of AGT or T1DM. To assess
the safety, efficacy, and mode of action of Abatacept to prevent AGT and T1DM.

The primary objective is to determine whether intervention with Abatacept will prevent or
delay the development of AGT in at-risk autoantibody positive non-diabetic relatives of
patients with T1DM.

Secondary outcomes include: the effect of Abatacept on the incidence of T1DM; analyses of
C-peptide and other measures from the OGTT; safety and tolerability; and mechanistic
outcomes.

Study Purpose and Rationale:

In this study, relatives who are confirmed to have two or more antibodies, not including
mIAA, and normal glucose tolerance will be eligible for randomization to experimental
treatment or placebo groups with the aim to determine whether experimental treatment will
prevent or delay the occurrence of abnormal glucose tolerance and type 1 diabetes mellitus.
Individuals with normal glucose tolerance are earlier in the disease process; that is, have
less beta cell destruction than those with abnormal glucose tolerance or frank diabetes, yet
will inevitably progress to clinical disease and essentially complete beta cell loss.
Treatment at this early stage in a population who will inevitably progress to type 1 diabetes
provides the greatest opportunity for a clinically important impact on disease prevention.
With abnormal glucose tolerance rather than diabetes as the primary endpoint, study
participants, regulators, funders, and investigators will be able to determine whether the
therapy can alter disease progression.

Therefore, the rationale for this study is that individuals with immunologic markers of T1DM
and normal glucose tolerance will inevitably develop clinical T1DM. Prior to development of
clinical T1DM they will progress from normal glucose tolerance to abnormal glucose tolerance;
and abnormal glucose tolerance results in clinical T1DM within 5 years in almost 80% of
subjects. They have a condition that differs from overt diabetes only in the duration of the
autoimmune process that results in beta cell destruction. Intervention early in the course of
disease may be more effective than intervention in those with abnormal glucose tolerance or
clinical T1DM.

Description of Treatment Groups

Subjects will be randomized to receive either Abatacept or placebo infusions along with close
monitoring for abnormal glucose tolerance or diabetes. The infusions will be conducted at
approved TrialNet clinical sites with appropriate facilities. All blood and serum samples for
the primary and secondary outcome determinations will be sent to the Core Laboratories for
analysis. Clinical laboratory studies may be done at the local sites.

Participants will be randomly assigned in a 1:1 ratio (within the two strata defined by age
at enrollment: <18 and 18 or older) to the following 2 groups:

- to receive Abatacept (intravenous infusion at 0, 2, and 4 weeks following randomization,
and then every 28+/-7 days) thereafter for a total of 14 doses. Close monitoring for
diabetes development through the duration of study.

- to receive placebo intravenous infusion at 0, 2, and 4 weeks following randomization and
then every 28+/- 7 days thereafter for a total of 14 doses. Close monitoring for
diabetes development through the duration of study.

Treatment Assignment

After participants sign the consent form, complete the screening visit(s), and meet all of
the inclusion criteria and none of the exclusion criteria, participants will be randomized to
receive either Abatacept and close monitoring or placebo with close monitoring.

Participants will be randomized in equal allocations to each group. The randomization method
will be stratified by TrialNet study site and whether the participant is less than 18 years
of age or 18 years and older. This approach ensures that study site will not be a potential
confounder. The TNCC will generate the randomization numbers and tables.

Study Assessments

During the course of the study, participants will frequently undergo assessments of their
glucose tolerance status, insulin production, immunologic status, and overall health and
well-being.

Samples will be drawn for storage in the National Institute for Diabetes and Digestive and
Kidney Disease (NIDDK) Repository and at TrialNet Laboratory Sites for future analysis
related to T1DM.

Study Duration

The study has been designed to provide 80% power to detect a 40% risk reduction in the
occurrence of abnormal glucose tolerance using a two-sided test at the 0.05 level after six
years of study duration. A total of approximately 206 patients will be allocated in a 1:1
ratio to the two groups.

Inclusion Criteria:

- Participant in TrialNet Natural History/Pathway to Prevention Study and thus, a
relative of a proband with T1DM.

- Between the ages of 1-45 years at the time of enrollment in TN01 and age ≥ 6 at time
of randomization in this trial.

- Willing to provide Informed Consent or have a parent or legal guardian provide
informed consent if the subject is <18 years of age.

- Normal glucose tolerance by OGTT confirmed within 7 weeks (no more than 52 days) of
baseline (visit 0). If previous abnormal glucose tolerance, has had two consecutive
OGTTs with normal glucose tolerance.

1. Fasting plasma glucose < 110 mg/dL (6.1 mmol/L), and

2. 2 hour plasma glucose <140 mg/dL (7.8 mmol/L), and

3. 30, 60, or 90 minute value on OGTT< 200mg/dL (11.1 mmol/L)

- At least two diabetes-related autoantibodies confirmed to be present on two occasions,
not including mIAA. Confirmation of 2 positive autoantibodies must occur within the
six months prior to randomization, but the confirmation does not have to involve the
same 2 autoantibodies.

- Weight ≥ 20 kg at Baseline Visit.

- If a female participant with reproductive potential, willing to avoid pregnancy and
undergo pregnancy testing prior to each infusion.

- At least three months from date of last live immunization.

- Willing to forgo live vaccines while receiving treatment on study and for three months
following last study drug administration.

Exclusion Criteria:

- Abnormal Glucose Tolerance or Diabetes

1. Fasting plasma glucose ≥ 110 mg/dL (6.1 mmol/L), or

2. 2 hour plasma glucose ≥ 140 mg/dL (7.8 mmol/L), or

3. 30, 60, 90 minute plasma glucose during OGTT ≥ 200 mg/dL (11.1 mmol/L)

- Insulin autoantibodies (mIAA).

- Are immunodeficient or have clinically significant chronic lymphopenia.

- Have an active infection at time of randomization.

- Have a positive PPD test result or history of previously treated TB, or positive
interferon-gamma release assay (IGRA) test.

- Be currently pregnant or lactating, or anticipate getting pregnant within 3 months of
the last study drug administration.

- Use of medications known to influence glucose tolerance.

- Require use of other immunosuppressive agents.

- Have serologic evidence of current or past HIV, Hepatitis B (positive for Hepatitis B
core antibody or surface antigen), or Hepatitis C infection.

- Have serological evidence of current CMV infection.

- Have evidence of active EBV infection.

- Have any complicating medical issues or abnormal clinical laboratory results that
interfere with study conduct or cause increased risk. These include pre-existing
cardiac disease, COPD, neurological, or blood count abnormalities (such as
lymphopenia, leukopenia, or thrombocytopenia).
We found this trial at
17
sites
Denver, Colorado 80045
Principal Investigator: Peter Gottlieb, MD
Phone: 303-315-0266
?
mi
from
Denver, CO
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
Principal Investigator: Louis Philipson, MD
Phone: 773-702-3853
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Gainesville, Florida 32610
(352) 392-3261
Principal Investigator: Desmond A. Schatz, MD
Phone: 352-294-5759
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
1200 Moursund Street
Houston, Texas 77030
(713) 798-4951
Principal Investigator: Maria Redondo, MD
Phone: 832-822-3380
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
(612) 625-5000
Principal Investigator: Antoinette Moran, MD
Phone: 612-624-6682
Univ of Minnesota With a flagship campus in the heart of the Twin Cities, and...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
116th St and Broadway
New York, New York 10027
(212) 854-1754
Principal Investigator: Robin Golan, MD
Phone: 212-851-5425
Columbia University In 1897, the university moved from Forty-ninth Street and Madison Avenue, where it...
?
mi
from
New York, NY
Click here to add this to my saved trials
4401 Penn Avenue
Pittsburgh, Pennsylvania 15224
412-692-5325
Principal Investigator: Dorothy Becker, MD
Phone: 412-692-5210
Children's Hospital of Pittsburgh of UPMC UPMC is one of the leading nonprofit health systems...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
4200 Fifth Ave
Pittsburgh, Pennsylvania 15260
(412) 624-4141
Principal Investigator: Dorothy Becker, MD
Phone: 412-692-5210
University of Pittsburgh The University of Pittsburgh is a state-related research university, founded as the...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: Philip Raskin, M.D.
Phone: 214-648-4844
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Indianapolis, Indiana 46202
Principal Investigator: Linda DiMeglio, MD
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Miami, Florida 33136
Principal Investigator: Jennifer Marks, MD
Phone: 305-243-3781
?
mi
from
Miami, FL
Click here to add this to my saved trials
2201 West End Ave
Nashville, Tennessee 37232
(615) 322-7311
Principal Investigator: William Russell, MD
Phone: 615-936-8638
Vanderbilt University Vanderbilt offers undergraduate programs in the liberal arts and sciences, engineering, music, education...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Haven, Connecticut 06520
Principal Investigator: Kevan Herold, MD
Phone: 203-737-2760
?
mi
from
New Haven, CT
Click here to add this to my saved trials
San Francisco, California 94143
Principal Investigator: Stephen Gitelman, MD
Phone: 415-514-3730
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Seattle, Washington 98101
Principal Investigator: Carla Greenbaum, MD
Phone: 800-888-4187
?
mi
from
Seattle, WA
Click here to add this to my saved trials
300 Pasteur Dr
Stanford, California 94305
(650) 723-4000
Principal Investigator: Darrell Wilson, MD
Phone: 650-498-4450
Stanford Univ Med Ctr The Medical Center is uniquely advantaged by its location on the...
?
mi
from
Stanford, CA
Click here to add this to my saved trials
555 University Avenue
Toronto, Ontario M5G 1X8
Principal Investigator: Diane Wherrett, MD
Phone: 416-813-8159
?
mi
from
Toronto,
Click here to add this to my saved trials